Cargando…

Pharmacokinetic interactions of herbal medicines for the treatment of chronic hepatitis

Chronic liver disease is a serious global health problem, and an increasing number of patients are seeking alternative medicines or complementary treatment. Herbal medicines account for 16.8% of patients with chronic liver disease who use complementary and alternative therapies. A survey of the Nati...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsueh, Tun-Pin, Lin, Wan-Ling, Tsai, Tung-Hu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taiwan Food and Drug Administration 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9332521/
https://www.ncbi.nlm.nih.gov/pubmed/28911662
http://dx.doi.org/10.1016/j.jfda.2016.11.010
_version_ 1784758668132089856
author Hsueh, Tun-Pin
Lin, Wan-Ling
Tsai, Tung-Hu
author_facet Hsueh, Tun-Pin
Lin, Wan-Ling
Tsai, Tung-Hu
author_sort Hsueh, Tun-Pin
collection PubMed
description Chronic liver disease is a serious global health problem, and an increasing number of patients are seeking alternative medicines or complementary treatment. Herbal medicines account for 16.8% of patients with chronic liver disease who use complementary and alternative therapies. A survey of the National Health Insurance Research Database in Taiwan reported that Long-Dan-Xie-Gan-Tang, Jia-Wei-Xia-Yao-San, and Xiao-Chai-Hu-Tang (Sho-saiko-to) were the most frequent formula prescriptions for chronic hepatitis used by traditional Chinese medicine physicians. Bioanalytical methods of herbal medicines for the treatment of chronic hepatitis were developed to investigate pharmacokinetics properties, but multicomponent herbal formulas have been seldom discussed. The pharmacokinetics of herbal formulas is closely related to efficacy, efficiency, and patient safety of traditional herbal medicines. Potential herbal formula–drug interactions are another essential issue during herbal formula administration in chronic hepatitis patients. In a survey with the PubMed database, this review article evaluates the existing evidence-based data associated with the documented pharmacokinetics profiles and potential herbal–drug interactions of herbal formulas for the treatment of chronic hepatitis. In addition, the existing pharmacokinetic profiles were further linked with clinical practice to provide insight for the safety and specific use of traditional herbal medicines.
format Online
Article
Text
id pubmed-9332521
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Taiwan Food and Drug Administration
record_format MEDLINE/PubMed
spelling pubmed-93325212022-08-09 Pharmacokinetic interactions of herbal medicines for the treatment of chronic hepatitis Hsueh, Tun-Pin Lin, Wan-Ling Tsai, Tung-Hu J Food Drug Anal Review Article Chronic liver disease is a serious global health problem, and an increasing number of patients are seeking alternative medicines or complementary treatment. Herbal medicines account for 16.8% of patients with chronic liver disease who use complementary and alternative therapies. A survey of the National Health Insurance Research Database in Taiwan reported that Long-Dan-Xie-Gan-Tang, Jia-Wei-Xia-Yao-San, and Xiao-Chai-Hu-Tang (Sho-saiko-to) were the most frequent formula prescriptions for chronic hepatitis used by traditional Chinese medicine physicians. Bioanalytical methods of herbal medicines for the treatment of chronic hepatitis were developed to investigate pharmacokinetics properties, but multicomponent herbal formulas have been seldom discussed. The pharmacokinetics of herbal formulas is closely related to efficacy, efficiency, and patient safety of traditional herbal medicines. Potential herbal formula–drug interactions are another essential issue during herbal formula administration in chronic hepatitis patients. In a survey with the PubMed database, this review article evaluates the existing evidence-based data associated with the documented pharmacokinetics profiles and potential herbal–drug interactions of herbal formulas for the treatment of chronic hepatitis. In addition, the existing pharmacokinetic profiles were further linked with clinical practice to provide insight for the safety and specific use of traditional herbal medicines. Taiwan Food and Drug Administration 2016-12-22 /pmc/articles/PMC9332521/ /pubmed/28911662 http://dx.doi.org/10.1016/j.jfda.2016.11.010 Text en © 2017 Taiwan Food and Drug Administration https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC-BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ).
spellingShingle Review Article
Hsueh, Tun-Pin
Lin, Wan-Ling
Tsai, Tung-Hu
Pharmacokinetic interactions of herbal medicines for the treatment of chronic hepatitis
title Pharmacokinetic interactions of herbal medicines for the treatment of chronic hepatitis
title_full Pharmacokinetic interactions of herbal medicines for the treatment of chronic hepatitis
title_fullStr Pharmacokinetic interactions of herbal medicines for the treatment of chronic hepatitis
title_full_unstemmed Pharmacokinetic interactions of herbal medicines for the treatment of chronic hepatitis
title_short Pharmacokinetic interactions of herbal medicines for the treatment of chronic hepatitis
title_sort pharmacokinetic interactions of herbal medicines for the treatment of chronic hepatitis
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9332521/
https://www.ncbi.nlm.nih.gov/pubmed/28911662
http://dx.doi.org/10.1016/j.jfda.2016.11.010
work_keys_str_mv AT hsuehtunpin pharmacokineticinteractionsofherbalmedicinesforthetreatmentofchronichepatitis
AT linwanling pharmacokineticinteractionsofherbalmedicinesforthetreatmentofchronichepatitis
AT tsaitunghu pharmacokineticinteractionsofherbalmedicinesforthetreatmentofchronichepatitis